Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial OfficerPRNewsWire • 06/23/23
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development OfficerPRNewsWire • 06/12/23
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate UpdatesPRNewsWire • 05/11/23
Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023PRNewsWire • 05/04/23
Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/17/23
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/23/23
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate UpdatesPRNewsWire • 03/23/23
Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023PRNewsWire • 03/13/23
Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023PRNewsWire • 03/10/23
Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in AdultsPRNewsWire • 03/06/23
Heron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare ConferencePRNewsWire • 02/27/23
Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan CapitalPRNewsWire • 02/22/23
Heron Therapeutics Highlights Progress in Acute Care and Oncology Care FranchisesPRNewsWire • 01/09/23